UNSPSC 51313407: Dexbrompheniramine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19BrN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75T64B71RP, chemically known as 3-(4-bromophenyl)-n,n-dimethyl-3-pyridin-2-yl-propan-1-amine but generally known as dexbrompheniramine, which bears US NIH Compound Identifier 16960. European Medicines Agency schedules Dexbrompheniramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07021MIG.

UNSPSC 51313407 Dexbrompheniramine is a Commodity code that in practice covers procurement of pharmaceuticals and related health products by state and local health agencies, but the recent opportunities tagged under this code show little connection to dexbrompheniramine specifically. Seminole County, Florida solicited naloxone and drug deactivation systems; the Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) called for generic multi-source pharmaceuticals and OTC products through a cooperative purchasing vehicle. These opportunities reflect broader pharmaceutical procurement — naloxone for opioid overdose response, direct pharmacy benefit management models, and generic drug supply agreements — rather than dexbrompheniramine demand. The issuing bodies span county health departments, state health agencies, and multistate cooperative purchasing alliances, indicating that pharmaceutical procurement under this code engages health systems across multiple levels of jurisdiction.

Recent activity centers on Florida, Texas, and the Minnesota-administered MMCAP cooperative serving multiple states including Oregon. Seminole County's IFB (Solicitation IFB60459723LAS) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (though posted June 30, 2026, the actual response deadline appears inconsistent with the posting date). Texas HHS issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription contracting, a preliminary market-intelligence phase before formal RFP issuance. MMCAP's RFP (S1070000015802), posted January 20, 2026, with questions due February 18, 2026, and proposals due March 26, 2026, establishes multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), effective July 1, 2026. The code shows limited recent activity specifically tied to dexbrompheniramine; state and local pharmaceutical procurement under this category is currently driven by opioid-response initiatives, pharmacy benefit program redesign, and cooperative generic drug supply agreements.